Back

CIRRUS­HCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy

18 May 2025 (10:58 - 11:06)
Organised by: Logo
Congress Presentation Part of: Hottest trials and trial updates (2) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Anjali Owens

University of Pennsylvania, Philadelphia (United States of America)

20 More presentations in this session

Presentation thumbnail
DIGIT­HF: Baseline characteristics compared to recent trials in heart failure with reduced ejection fraction
Professor U. Bavendiek (Hannover, DE)
Slides Video
Presentation thumbnail
Discussant review - DIGIT­HF
Professor D. van Veldhuisen (Groningen, NL)
Slides Video
Presentation thumbnail
Panel discussion - DIGIT­HF
Video
Presentation thumbnail
Discussant review - CIRRUS­HCM
Professor I. Olivotto (Florence, IT)
Slides Video
Presentation thumbnail
Panel discussion - CIRRUS­HCM
Video

Access the full session

Session thumbnail
Hottest trials and trial updates (2)
Video

The Event

Event poster

Heart Failure 2025

18 May 2025 10:58 CET
You may be interested in
thumbnail
Congress Session
Advances in cardiomyopathies
11 May 2026
thumbnail
Congress Presentation
REDWOOD-HCM OLE: aficamten in HCM
23 May 2022
thumbnail
Congress Presentation
ODYSSEY-HCM: Mavacamten in nHCM
30 August 2025
thumbnail
Congress Presentation
Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources